US5869451A
(en)
*
|
1995-06-07 |
1999-02-09 |
Glaxo Group Limited |
Peptides and compounds that bind to a receptor
|
ZA964814B
(en)
*
|
1995-06-07 |
1998-02-09 |
Glaxo Group Ltd |
Peptides and compounds that bind to a receptor.
|
US6251864B1
(en)
|
1995-06-07 |
2001-06-26 |
Glaxo Group Limited |
Peptides and compounds that bind to a receptor
|
US7091311B2
(en)
|
1996-06-07 |
2006-08-15 |
Smithkline Beecham Corporation |
Peptides and compounds that bind to a receptor
|
US7083983B2
(en)
*
|
1996-07-05 |
2006-08-01 |
Cancer Research Campaign Technology Limited |
Inhibitors of the interaction between P53 and MDM2
|
JP2001521897A
(ja)
*
|
1997-10-31 |
2001-11-13 |
スミスクライン・ビーチャム・コーポレイション |
新規な金属錯体
|
CA2308317A1
(en)
|
1997-10-31 |
1999-05-14 |
Smithkline Beecham Corporation |
Novel metal complexes
|
AU748063B2
(en)
|
1997-10-31 |
2002-05-30 |
Ligand Pharmaceuticals Incorporated |
Novel metal complexes
|
US7488590B2
(en)
|
1998-10-23 |
2009-02-10 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
TWI257394B
(en)
|
1998-10-23 |
2006-07-01 |
Kirin Amgen Inc |
Thrombopoietic compounds
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
WO2001021259A2
(en)
*
|
1999-09-21 |
2001-03-29 |
Emory University |
Use and compositions for treating platelet-related disorders using anagrelide
|
US20030190644A1
(en)
|
1999-10-13 |
2003-10-09 |
Andreas Braun |
Methods for generating databases and databases for identifying polymorphic genetic markers
|
US6808902B1
(en)
|
1999-11-12 |
2004-10-26 |
Amgen Inc. |
Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
|
IL149340A0
(en)
|
1999-11-18 |
2002-11-10 |
Corvas Int Inc |
Nucleic acids encoding endotheliases, endotheliases and uses thereof
|
TWI284639B
(en)
*
|
2000-01-24 |
2007-08-01 |
Shionogi & Co |
A compound having thrombopoietin receptor agonistic effect
|
US7700341B2
(en)
*
|
2000-02-03 |
2010-04-20 |
Dendreon Corporation |
Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
|
AU5943201A
(en)
*
|
2000-05-03 |
2001-11-12 |
Amgen Inc |
Modified peptides as therapeutic agents
|
US20050158838A1
(en)
*
|
2000-06-19 |
2005-07-21 |
Dyax Corp., A Delaware Corporation |
Novel enterokinase cleavage sequences
|
US7396917B2
(en)
*
|
2000-12-05 |
2008-07-08 |
Alexion Pharmaceuticals, Inc. |
Rationally designed antibodies
|
ATE414720T1
(de)
*
|
2000-12-05 |
2008-12-15 |
Alexion Pharma Inc |
Rationell entworfene antikörper
|
US20040253242A1
(en)
*
|
2000-12-05 |
2004-12-16 |
Bowdish Katherine S. |
Rationally designed antibodies
|
AU2002305052A1
(en)
|
2001-03-13 |
2002-09-24 |
Corvas International, Inc. |
Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
|
US7172892B2
(en)
|
2001-03-22 |
2007-02-06 |
Dendreon Corporation |
Nucleic acid molecules encoding serine protease CVSP14, the encoded polypeptides and methods based thereon
|
US7105333B2
(en)
|
2001-03-27 |
2006-09-12 |
Deadreon Corporation |
Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
|
KR20040080940A
(ko)
|
2001-05-14 |
2004-09-20 |
덴드레온 코포레이션 |
트랜스막 세린 프로테아제 10을 암호화하는 핵산 분자,암호화된 폴리펩티드 및 이에 근거한 방법
|
US7332474B2
(en)
*
|
2001-10-11 |
2008-02-19 |
Amgen Inc. |
Peptides and related compounds having thrombopoietic activity
|
US20030134794A1
(en)
*
|
2001-11-20 |
2003-07-17 |
Madison Edwin L. |
Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
|
US20030191056A1
(en)
|
2002-04-04 |
2003-10-09 |
Kenneth Walker |
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
|
IL158569A0
(en)
*
|
2002-06-29 |
2004-05-12 |
Aquanova Ger Solubilisate Tech |
Isoflavone concentrates and methods for the production thereof
|
US20040028661A1
(en)
*
|
2002-08-07 |
2004-02-12 |
Bartelmez Stephen H. |
Expansion of cells using thrombopoietin and anti-transforming growth factor-beta
|
JP4412173B2
(ja)
|
2002-08-14 |
2010-02-10 |
日産化学工業株式会社 |
トロンボポエチンレセプター活性化剤ならびにそれらの製造方法
|
US8227411B2
(en)
*
|
2002-08-20 |
2012-07-24 |
BioSurface Engineering Technologies, Incle |
FGF growth factor analogs
|
US7598224B2
(en)
|
2002-08-20 |
2009-10-06 |
Biosurface Engineering Technologies, Inc. |
Dual chain synthetic heparin-binding growth factor analogs
|
US7166574B2
(en)
*
|
2002-08-20 |
2007-01-23 |
Biosurface Engineering Technologies, Inc. |
Synthetic heparin-binding growth factor analogs
|
MXPA05003057A
(es)
*
|
2002-09-18 |
2006-04-18 |
Johnson & Johnson |
Metodos para aumentar la produccion de celulas madre hematopoyeticas y plaquetas.
|
TWI324593B
(en)
|
2002-10-09 |
2010-05-11 |
Nissan Chemical Ind Ltd |
Pyrazolone compounds and thrombopoietin receptor activator
|
EP2241330A1
(en)
|
2003-02-14 |
2010-10-20 |
The Curators Of The University Of Missouri |
Contraceptive methods and compositions related to proteasomal interference
|
WO2004101600A2
(en)
*
|
2003-05-12 |
2004-11-25 |
Affymax, Inc. |
Novel poly(ethylene glycol) modified compounds and uses thereof
|
ES2323465T3
(es)
*
|
2003-05-12 |
2009-07-16 |
Affymax, Inc. |
Peptidos novedosos que se unen al receptor de la eritropoyetina.
|
MXPA05012314A
(es)
*
|
2003-05-12 |
2006-04-18 |
Affymax Inc |
Radical separador para peptido modificado con polietilenglicol.
|
ES2395413T3
(es)
*
|
2003-05-12 |
2013-02-12 |
Affymax, Inc. |
Péptidos que se unen al receptor de eritropoyetina
|
CN103130739B
(zh)
*
|
2003-08-12 |
2015-09-16 |
盐野义制药株式会社 |
具有血小板生成素受体激动作用的化合物
|
CN102241742B
(zh)
*
|
2003-08-28 |
2014-04-02 |
奥索-麦克尼尔药品公司 |
结合血小板生成素受体的肽和化合物
|
US7723295B2
(en)
*
|
2003-08-28 |
2010-05-25 |
Ortho-Mcneil Pharmaceutical, Inc. |
Peptides and compounds that bind to a receptor
|
EP1701969B1
(en)
|
2003-12-31 |
2007-10-24 |
F.Hoffmann-La Roche Ag |
Process for peptide synthesis using a reduced amount of deprotection agent
|
US7414028B1
(en)
*
|
2004-02-04 |
2008-08-19 |
Biosurface Engineering Technologies, Inc. |
Growth factor analogs
|
US20060024347A1
(en)
*
|
2004-02-10 |
2006-02-02 |
Biosurface Engineering Technologies, Inc. |
Bioactive peptide coatings
|
US20080227696A1
(en)
*
|
2005-02-22 |
2008-09-18 |
Biosurface Engineering Technologies, Inc. |
Single branch heparin-binding growth factor analogs
|
US7671012B2
(en)
|
2004-02-10 |
2010-03-02 |
Biosurface Engineering Technologies, Inc. |
Formulations and methods for delivery of growth factor analogs
|
US7528105B1
(en)
|
2004-02-10 |
2009-05-05 |
Biosurface Engineering Technologies |
Heterodimeric chain synthetic heparin-binding growth factor analogs
|
JP4895826B2
(ja)
|
2004-02-20 |
2012-03-14 |
バイオサーフェス エンジニアリング テクノロジーズ,インク. |
骨形成蛋白−2の正のモジュレーター
|
WO2006010057A2
(en)
*
|
2004-07-08 |
2006-01-26 |
Amgen Inc. |
Therapeutic peptides
|
US20060210542A1
(en)
*
|
2004-08-16 |
2006-09-21 |
Yurkow Edward J |
Use of TPO mimetic compounds and pharmaceutical compositions in the treatment of anemia
|
BRPI0516011A
(pt)
*
|
2004-09-24 |
2008-08-19 |
Amgen Inc |
moléculas fc modificadas
|
US7589063B2
(en)
|
2004-12-14 |
2009-09-15 |
Aplagen Gmbh |
Molecules which promote hematopoiesis
|
JP2008519858A
(ja)
*
|
2004-11-11 |
2008-06-12 |
アフィーマックス・インコーポレイテッド |
エリスロポエチンレセプターに結合する新規ペプチド
|
WO2006062685A2
(en)
*
|
2004-11-11 |
2006-06-15 |
Affymax, Inc. |
Novel peptides that bind to the erythropoietin receptor
|
CA2588979C
(en)
|
2004-12-08 |
2013-01-22 |
Nissan Chemical Industries, Ltd. |
3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators
|
WO2006064957A1
(ja)
|
2004-12-14 |
2006-06-22 |
Nissan Chemical Industries, Ltd. |
アミド化合物及びトロンボポエチンレセプター活性化剤
|
EP1861417B1
(en)
|
2005-03-10 |
2013-05-15 |
BioNTech AG |
Dimeric or multimeric microproteins
|
WO2006094530A1
(en)
*
|
2005-03-11 |
2006-09-14 |
Siegfried Ltd. |
Di-polymer protein conjugates and processes for their preparation
|
US7919461B2
(en)
|
2005-06-03 |
2011-04-05 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US8324159B2
(en)
*
|
2005-06-03 |
2012-12-04 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US7550433B2
(en)
*
|
2005-06-03 |
2009-06-23 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
CA2648732A1
(en)
*
|
2005-06-23 |
2006-12-28 |
Aplagen Gmbh |
Supravalent compounds
|
TWI368617B
(en)
|
2005-07-15 |
2012-07-21 |
Nissan Chemical Ind Ltd |
Thiophene compounds and thrombopoietin receptor activators
|
WO2007011056A1
(en)
|
2005-07-20 |
2007-01-25 |
Nissan Chemical Industries, Ltd. |
Pyrazole compounds and thrombopoietin receptor activators
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
EP1947101A4
(en)
|
2005-11-07 |
2009-09-16 |
Nissan Chemical Ind Ltd |
HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR
|
WO2007102946A2
(en)
|
2006-01-23 |
2007-09-13 |
Amgen Inc. |
Crystalline polypeptides
|
US7879318B2
(en)
*
|
2006-01-23 |
2011-02-01 |
Mcw Research Foundation, Inc. |
Method of reducing the effects of ischemia by administration of a thrombopoietin receptor ligand
|
CA2635498A1
(en)
*
|
2006-01-25 |
2007-08-02 |
Amgen Inc. |
Thrombopoietic compounds
|
EP1834963A1
(en)
*
|
2006-03-13 |
2007-09-19 |
Siegfried Ltd. |
Di-polymer protein conjugates and processes for their preparation
|
DE602007009954D1
(de)
|
2006-03-22 |
2010-12-02 |
Viral Logic Systems Technology |
Verfahren zur identifizierung von polypeptid-targets
|
JO3324B1
(ar)
|
2006-04-21 |
2019-03-13 |
Amgen Inc |
مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
|
US8377448B2
(en)
*
|
2006-05-15 |
2013-02-19 |
The Board Of Trustees Of The Leland Standford Junior University |
CD47 related compositions and methods for treating immunological diseases and disorders
|
US20080131431A1
(en)
*
|
2006-05-15 |
2008-06-05 |
Viral Logic Systems Technology Corp. |
CD47 related compositions and methods for treating immunological diseases and disorders
|
US7820172B1
(en)
|
2006-06-01 |
2010-10-26 |
Biosurface Engineering Technologies, Inc. |
Laminin-derived multi-domain peptides
|
WO2007142308A1
(ja)
|
2006-06-07 |
2007-12-13 |
Nissan Chemical Industries, Ltd. |
含窒素ヘテロ環化合物及びトロンボポエチンレセプター活性化剤
|
US7981425B2
(en)
|
2006-06-19 |
2011-07-19 |
Amgen Inc. |
Thrombopoietic compounds
|
CA2692240C
(en)
|
2006-06-22 |
2018-03-13 |
Biosurface Engineering Technologies, Inc. |
Composition and method for delivery of bmp-2 amplifier/co-activator for enhancement of osteogenesis
|
US20090252703A1
(en)
*
|
2006-10-19 |
2009-10-08 |
Gegg Jr Colin V |
Use of alcohol co-solvents to improve pegylation reaction yields
|
EP2118127A4
(en)
*
|
2007-01-31 |
2010-12-01 |
Affymax Inc |
NICKET-BASED LINKER FOR BONDING MODIFYING GROUPS OF POLYPEPTIDES AND OTHER MACROMOLECULES
|
EP2162540A2
(en)
|
2007-05-22 |
2010-03-17 |
Amgen Inc. |
Compositions and methods for producing bioactive fusion proteins
|
WO2008157824A2
(en)
*
|
2007-06-21 |
2008-12-24 |
Conjuchem Biotechnologies Inc. |
Thrombopoietin peptide conjugates
|
US20090088371A1
(en)
*
|
2007-08-28 |
2009-04-02 |
Rigel Pharmaceuticals, Inc. |
Combination therapy with syk kinase inhibitor
|
US8183342B2
(en)
*
|
2007-11-06 |
2012-05-22 |
Case Western Reserve University |
Method of treating chemotherapy-induced thrombocytopenia
|
CN101481352A
(zh)
|
2008-01-10 |
2009-07-15 |
上海恒瑞医药有限公司 |
双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用
|
US9175078B2
(en)
|
2008-01-25 |
2015-11-03 |
Amgen Inc. |
Ferroportin antibodies and methods of use
|
CA2722600C
(en)
|
2008-05-01 |
2014-01-21 |
Amgen Inc. |
Anti-hepcidin antibodies and methods of use
|
MX347291B
(es)
|
2009-03-20 |
2017-04-17 |
Amgen Inc |
Inmunoglobulinas portadoras y usos de las mismas.
|
WO2011012306A2
(en)
|
2009-07-30 |
2011-02-03 |
Aplagen Gmbh |
Use of emps for antagonising epo-stimulatory effects on epo-responsive tumors while maintaining erythropoiesis
|
WO2011049213A1
(ja)
|
2009-10-23 |
2011-04-28 |
日産化学工業株式会社 |
縮環へテロ環化合物及びトロンボポエチンレセプター活性化剤
|
WO2011098095A1
(en)
|
2010-02-09 |
2011-08-18 |
Aplagen Gmbh |
Peptides binding the tpo receptor
|
EA201370076A1
(ru)
|
2010-09-22 |
2013-08-30 |
Амген Инк. |
Иммуноглобулины-переносчики и их применение
|
WO2014159242A1
(en)
|
2013-03-14 |
2014-10-02 |
Novartis Ag |
Notch 3 mutants and uses thereof
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
TN2017000084A1
(en)
|
2014-09-11 |
2018-07-04 |
Bristol Myers Squibb Co |
Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions
|
US9732119B2
(en)
|
2014-10-10 |
2017-08-15 |
Bristol-Myers Squibb Company |
Immunomodulators
|
US9856292B2
(en)
|
2014-11-14 |
2018-01-02 |
Bristol-Myers Squibb Company |
Immunomodulators
|
US11270782B2
(en)
|
2014-11-19 |
2022-03-08 |
Koninklijke Philips N.V. |
Diagnostic method employing HNL
|
US9861680B2
(en)
|
2014-12-18 |
2018-01-09 |
Bristol-Myers Squibb Company |
Immunomodulators
|
US9944678B2
(en)
|
2014-12-19 |
2018-04-17 |
Bristol-Myers Squibb Company |
Immunomodulators
|
US20160222060A1
(en)
|
2015-02-04 |
2016-08-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
US9809625B2
(en)
|
2015-03-18 |
2017-11-07 |
Bristol-Myers Squibb Company |
Immunomodulators
|
US10143746B2
(en)
|
2016-03-04 |
2018-12-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
US10358463B2
(en)
|
2016-04-05 |
2019-07-23 |
Bristol-Myers Squibb Company |
Immunomodulators
|
LT3458111T
(lt)
|
2016-05-19 |
2021-05-25 |
Bristol-Myers Squibb Company |
Pet vizualizacijos imunomoduliatoriai
|
US10988507B2
(en)
|
2016-11-07 |
2021-04-27 |
Bristol-Myers Squibb Company |
Immunomodulators
|
KR20200020858A
(ko)
|
2017-06-23 |
2020-02-26 |
브리스톨-마이어스 스큅 컴퍼니 |
Pd-1의 길항제로서 작용하는 면역조정제
|
CA3070442A1
(en)
*
|
2017-07-26 |
2019-01-31 |
Janssen Pharmaceutica Nv |
Methods of protecting vascular integrity induced by targeted radiation therapy
|
KR20200058506A
(ko)
|
2017-10-03 |
2020-05-27 |
브리스톨-마이어스 스큅 컴퍼니 |
면역조정제
|
MA54821A
(fr)
|
2019-01-25 |
2021-12-01 |
Janssen Pharmaceutica Nv |
Méthodes pour augmenter la protection contre les lésions des organes et des vaisseaux, la récupération hématopoïétique et la survie en réponse à une exposition à une irradiation corporelle totale ou à des agents chimiques
|
CA3127455A1
(en)
*
|
2019-01-25 |
2020-07-30 |
Janssen Pharmaceutica Nv |
Methods for mitigating liver injury and promoting liver hypertrophy, regeneration and cell engraftment in conjunction with radiation and/or radiomimetic treatments
|
WO2020209920A2
(en)
|
2019-01-25 |
2020-10-15 |
Janssen Pharmaceutica Nv |
Methods of mitigating toxic effects of vesicants and caustic gas
|
US20230104658A1
(en)
|
2021-10-01 |
2023-04-06 |
Janssen Pharmaceutica Nv |
Methods of increasing progenitor cell production
|
WO2024095178A1
(en)
|
2022-11-01 |
2024-05-10 |
Janssen Pharmaceutica Nv |
Thrombopoietin mimetic for use in the treatment of acute liver failure
|